These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33246984)

  • 21. Combined inhibition/silencing of diacylglycerol kinase α and ζ simultaneously and synergistically enhances interleukin-2 production in T cells and induces cell death of melanoma cells.
    Takao S; Akiyama R; Sakane F
    J Cell Biochem; 2021 May; 122(5):494-506. PubMed ID: 33399248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.
    Binder DC; Engels B; Arina A; Yu P; Slauch JM; Fu YX; Karrison T; Burnette B; Idel C; Zhao M; Hoffman RM; Munn DH; Rowley DA; Schreiber H
    Cancer Immunol Res; 2013 Aug; 1(2):123-33. PubMed ID: 24455752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The diacylglycerol kinase ζ inhibitor ASP1570 augments natural killer cell function.
    Okumura M; Yokoyama Y; Yoshida T; Okada Y; Takizawa M; Ikeda O; Kambayashi T
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111145. PubMed ID: 37935092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
    Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
    Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diacylglycerol kinase ζ limits B cell antigen receptor-dependent activation of ERK signaling to inhibit early antibody responses.
    Wheeler ML; Dong MB; Brink R; Zhong XP; DeFranco AL
    Sci Signal; 2013 Oct; 6(297):ra91. PubMed ID: 24129701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High DGK-α and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention.
    Prinz PU; Mendler AN; Masouris I; Durner L; Oberneder R; Noessner E
    J Immunol; 2012 Jun; 188(12):5990-6000. PubMed ID: 22573804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
    Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
    Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals.
    Arranz-Nicolás J; Ogando J; Soutar D; Arcos-Pérez R; Meraviglia-Crivelli D; Mañes S; Mérida I; Ávila-Flores A
    Cancer Immunol Immunother; 2018 Jun; 67(6):965-980. PubMed ID: 29572701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conditional Deletion of
    Raghavan S; Tovbis-Shifrin N; Kochel C; Sawant A; Mello M; Sathe M; Blumenschein W; Muise ES; Chackerian A; Pinheiro EM; Rosahl TW; Luche H; de Waal Malefyt R
    Front Immunol; 2021; 12():752348. PubMed ID: 34912335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
    Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-1
    Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Szomolay B; Ott S; Dolton G; Lyngaa R; Hadrup SR; Sewell AK; Svane IM
    Clin Cancer Res; 2017 Oct; 23(19):5779-5788. PubMed ID: 28679768
    [No Abstract]   [Full Text] [Related]  

  • 35. CD8
    Dumont C; Jacquier A; Verine J; Noel F; Goujon A; Wu CL; Hung TM; Desgrandchamps F; Culine S; Carosella ED; Rouas-Freiss N; LeMaoult J
    Cancer Immunol Res; 2019 Oct; 7(10):1619-1632. PubMed ID: 31451484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.
    Menger L; Sledzinska A; Bergerhoff K; Vargas FA; Smith J; Poirot L; Pule M; Hererro J; Peggs KS; Quezada SA
    Cancer Res; 2016 Apr; 76(8):2087-93. PubMed ID: 27197251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity.
    Ren Z; Zhang A; Sun Z; Liang Y; Ye J; Qiao J; Li B; Fu YX
    J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 35104810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional tumor specific CD8 + T cells in spleen express a high level of PD-1.
    Wang Z; Chen T; Lin W; Zheng W; Chen J; Huang F; Xie X
    Int Immunopharmacol; 2020 Mar; 80():106242. PubMed ID: 32014811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.